Medscape reports that the FDA has approved Audenz, “the first and only
adjuvanted, cell-based pandemic vaccine to provide active immunization against
the influenza A virus H5N1 strain.” According to Medscape, “Influenza A (H5N1)
monovalent vaccine, adjuvanted...is for use in individuals aged 6 months and
older.” The vaccine is “designed to be rapidly deployed to help protect the US
population and can be stockpiled for first responders in the event of a
pandemic.”
Healio also covers the story.
